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Abstract 
In this study, a library of arylstibonic acids were screened as potential protein tyrosine 
phosphatase inhibitors. Two compounds, namely 13778 and P6949 were identified as potent 
Cdc25 phosphatase inhibitors, an important key regulator of the eukaryotic cell cycle. These 
arylstibonic acids were also tested against other members of the protein tyrosine phosphatase 
family and were found to display good specificity and potency for Cdc25 phosphatases.  
Introduction 
 
Phosphatases are important regulators of many cellular functions, which in turn impact 
disease and human health. In particular, protein tyrosine phosphatases (PTPs), which counteract the 
many protein tyrosine kinases involved in cellular signaling, and have a significant role in the 
development of cancer, diabetes and obesity (1, 2). The PTP family is defined by its homology in the 
phosphatase domain, which is characterized by a cysteine separated by five amino acids from an 
arginine (CX5R motif). Within this family of CX5R phosphatases are the cell division cycle 25 (Cdc25) 
phosphatases, which play a key role in cell cycle regulation by controlling cyclin-dependent kinase 
dephosphorylation and activation (3). There are three isoforms of Cdc25 phosphatases encoded by the 
human genome, namely Cdc25a, Cdc25b and Cdc25c.  Cdc25a appears to regulate the G1/S transition, 
whereas Cdc25b and Cdc25c both are regulators of the S/G2 transition (4).  It has been reported that 
Cdc25 phosphatases, in particular Cdc25a and Cdc25b, are over-expressed in various primary human 
cancers (5). Therefore, Cdc25 phosphatases are potential targets for anticancer therapeutics. 
Results and Discussion 
Recently, arylstibonic acids have been characterized as potent inhibitors of the DNA repair 
endonuclease APE1 and type 1B topoisomerases (6, 7).  Interestingly, APE1 shares some homology 
in its catalytic site with the type II phophoinositide 5-phosphatase (5’-P) active site of the 
synaptojanins, which is distinct from the active sites of the CX5R family of phosphatases (8).  From 
this homology we surmised that the arylstibonates might selectively target the 5’-P active site of 
synaptojanin.  Instead, we surprisingly found that a subset of these arylstibonates were potent and 
isoform selective Cdc25 phosphatase inhibitors. 
We began by performing a preliminary screen of the arylstibonic acid library against the 
activities of representative phosphatases from the 5’-P and CX5R families. Interestingly, in addition to 
its 5’-P activity, synaptojanin also contains an independent phosphatase active site, referred to as 
SAC1, which is related to the CX5R family of the PTPs.  Thus, we had the opportunity to assess the 
selectivity of these arylstibonates for either active site in a single bifunctional enzyme.  In addition, 
we also screened PTP-ß, another CX5R family member.  We used screening conditions where the 
substrate concentration was fixed near its KM, employing just 5 µM of each arylstibonate.  This screen 
revealed that some compounds provided 40-50% inhibition of the 5’-P activity of synaptojanin under 
these conditions, consistent with the expectation based on APE1 homology (6).  However, the 
structurally unrelated CX5R phosphatases SAC1 and PTP-β were found to be much better targets for 
several compounds (Figure 1).  
 
 
Figure 1. Inhibition of synaptojanin, SAC1 and PTP-β activities by arylstibonic acids.  
(Top panel) A library of arylstibonic acids were screened in activity assays against synaptojanin, SAC1 and 
PTP-β. Shown are the percentages of inhibition in the presence of 5 μM of arylstibonic acids. The most potent 
compounds for synaptojanin (≥ 40% inhibition), SAC1 (≥ 40% inhibition) and PTP-β (≥ 90% inhibition) are 
shown. The activity of synaptojanin was measured in the presence of 50 µM PI(4)P presented in octylglucoside 
mixed micelles; SAC activity was assessed using 50 µM I(1,4,5)P3 as substrate and PTP-β activity was assessed 
using 1 mM p-NPP substrate. Error bars represent the standard error of triplicate repeats. (Bottom panel) 
Chemical structures of arylstibonic acids inhibiting synaptojanin, SAC domain and PTP-β. For the full list of 
tested arylstibonates refer to (7). All other compounds showed an inhibition of less than 40% against the tested 
enzymes (data not shown). 
 
The most potent inhibition was observed against PTP-ß, with several compounds 
(13755, P6953, 13778, P6968, P6981, P6949) nearly wiping out phosphatase activity at 5 µM 
inhibitor concentration.  We then performed a full dose response study over the range 50 nM 
to 5 M using the four most selective and effective PTP-ß phosphatase inhibitors and 
employing p-NPP as substrate (Fig. 2).  We found that compounds 13778 and P6949 were the 
most potent inhibitors (IC50 ~100 nanomolar range). 
 
Figure 2. Potency of selected arylstibonates on tyrosine phosphatase activity.   
PTP-β inhibitors identified in the screen presented in Fig. 1 were tested for their potency in the presence of 
enzyme with increasing concentrations of the arylstibonates 13778 and P6949. Error bars represent the standard 
error of triplicate repeats. 
 
The initial screen of the arystibonic acid library of 40 compounds, which have discrete 
structural differences, allows us the assessment of structure-function relationships. The screen 
using 5 µM of arystibonates reveal that substitution in the aromatic ring is vital for 
compounds inhibitory effect, as arylstibonate 13744 does not show any inhibitory effect 
towards PTP-β (see Table 1). Interestingly, the positioning of aromatic substitution does not 
have a significant effect on PTP- β inhibition, as demonstrated by comparing compound 
13759 and 13760. However, carboxylic acid rather than nitro functionality seems to be more 
important for PTP-β inhibition. Removal of the nitro group lessened inhibition (13760) but 
the decrease in inhibition observed when the carboxylic acid is removed is more severe 
(13743). Twelve out of the thirteen carboxylic acid functional compounds in the library 
inhibited PTP- β by more than 60% again highlighting the dependence of PTP inhibition on 
carboxylic acid functionality. The interaction between the stibonates and PTP- β compound is 
clearly controlled by electrostatic interaction. If the carboxylic acid COOH group is replaced 
the less electronegative hydroxyl group, (comparing 13745 with 13760), then inhibition is 
abolished. Replacing the COOH with ester functionality also abolishes the inhibition (13771 
and P6983). Extending the length of the carboxylated side chain greatly improves the potency 
of compound 13759, making 13778 and P6949 highly potent inhibitors.  
 
 
 
Compound (5 μM) X Y Inhibition of PTP-β 
13744 H H No inhibition 
13759 CO2H H 78% 
13760 H CO2H 72% 
P6966 CO2H CO2H 51% 
13771 CO2CH3 H No inhibition 
P6983 CH2CH(CO2Et)2 H No inhibition 
13778 C2H2CO2H H ≥ 90% 
P6949 C2H4CO2H H ≥ 90% 
13743 NO2 H 50% 
P6981 CH2CH(CO2H)2 H ≥90% 
P6982 H CH2CH(CO2H)2 67% 
13755 NO2 CO2H ≥90% 
13745 H OH No inhibition 
 
Table 1. Structure activity relationships of arylstibonic acids as PTP-β inhibitors. 
 
The finding that arylstibonates were potent inhibitors of PTP-β prompted the testing 
of 13778 and P6949 against a panel of nine CX5R family members using the artificial 
substrate O-methylfluorescein phosphate (OMFP) (see Table 2).  Included in this panel were 
several enzymes (Cdc25s, PTEN, MKP-3, VHR, and PTPMT1) that are members of the dual-
specificity phosphatase (DSP) subfamily which are characterized by a broader substrate 
specificity. Although they share the same catalytic mechanism as the classical PTPs, the DSP 
active site allows these enzymes to accommodate phosphoserine, phosphothreonine, 
phosphotyrosine and even non-protein substrates.  After determining the KM and Vmax values 
of each enzyme for OMFP (not shown), dose response curves for arylstibonates 13778 and 
P6949 were then constructed using OMFP concentrations near the KM value for each enzyme 
(Fig. 3). Arylstibonate 13778 and P6949 were found to inhibit some of the tested PTPs with 
even higher potency than PTP-β. The best potency was observed for arylstibonate 13778 
against Cdc25a phosphatase with an IC50 = 0.11 ± 0.01 μM, followed by Cdc25b (IC50 = 0.60 
± 0.07 μM). Interestingly, the activity of Cdc25c was not sufficiently affected by even 10 µM 
of compound 13778, which indicates that 13778 has an isoform-selectivity against Cdc25 
phosphatases. Another inhibited phosphatase was PTPMT1 (IC50 = 1.62 µM ± 0.19 μM), 
which was recently identified as a DSP anchored at the inner membrane of the mitochondria 
(9).  PTP1B is inhibited by 13778 with an IC50 of ~ 8 µM which is over 10-fold higher than 
PTP-, once again showing the potential for significant selectivity of these compounds, even 
when the active site sequences of the enzymes are closely matched (see below). 
Arylstibonate P6949 showed similar selectivity as 13778 (Fig. 3b). Cdc25a, 25b as 
well as PTP-β were the best targets, while Cdc25c was not affected at the concentrations 
tested, once again underlining the isoform-selectivity of these inhibitors within the Cdc25 
family. Similar selectivity by compounds 13778 and P6949 is expected based on their similar 
structures, which only differ by the presence of the double bond in the carboxylate side chain 
of 13778.  However, despite their similar selectivities, the potency of compound P6949 is 
significantly lower than that of 13778 (~30-fold lower for Cdc25a and about 10-fold lower 
for Cdc25b), indicating a significant beneficial contribution from the double bond-containing 
side chain of 13778.  We determined that the inhibition was reversible for both compounds 
using a standard dilution approach, where the enzyme was pre-incubated with four times the 
IC50 concentration of the arylstibonate inhibitor, followed by a 10-fold dilution with reaction 
buffer (Fig. 4)(10).   
 
 Figure 3. Potency of arylstibonate 13778 and P6949 on members of the PTP family. 
(a) IC50 curves of PTPs in the presence of arylstibonate 13778. (b) IC50 curves of PTPs in the presence of 
arylstibonate P6949. Data shown are the average of 3 independent experiments performed in triplicates. 
(c) Alignment of amino acid sequences of the catalytic motif of PTPs assayed.  
 
 
 
 
 
 
 
Table 2. IC50 values of PTPs assayed in the presence of 13778 and P6949 using OMFP as substrate.   
 
Enzyme 
 
IC50 – 13778 
 
IC50 – P6949 
 
Cdc25a 0.11 ± 0.01 µM 3.15 ± 0.13 µM 
Cdc25b 0.60 ± 0.07 µM 5.67 ± 0.48 µM 
Cdc25c >> 10 µM >> 100 µM 
VHR >> 10 µM >> 100 µM 
PTP-β 0.77 ± 0.29 µM 1.62 ± 0.92 µM 
MKP-3 >> 10 µM >> 100 µM 
PTP 1B 7.93 ± 3.95 µM >> 100 µM 
PTEN ~ 10 µM 8.87 ± 1.02 µM 
PTP MT1 1.62 ± 0.19 µM 13.44 ± 1.21 µM 
 Figure 4. Mode of inhibition of Cdc25a and 25b by 13778 and P6949 is reversible and mixed-type. 
(a) Reversibility of inhibition as determined by dilution assay. Cdc 25 phosphatases were incubated with 4 times 
the IC50s concentrations of either 13778 or P6949, respectively. The enzyme-inhibitor mixture was diluted 10-
fold using reaction buffer and enzyme activity was assayed as above. Activity is shown as the percentage of 
uninhibited reaction. (b and c) Michaelis–Menten plots of Cdc25a activity using OMFP as substrate in the 
presence of either 13778 or P6949 at concentrations as indicated. (d and e) Michaelis–Menten plots of Cdc25b 
activity using OMFP as substrate in the presence of either 13778 or P6949 at concentrations as indicated. 
 
In order to investigate the mode of inhibition, we studied the steady-state kinetic 
parameters of Cdc25a and 25B in the presence of varying inhibitor concentrations. As shown 
in Fig. 4, the apparent Km values for both enzymes increase as the concentrations of 13778 
and P6949 increase, and that Vmax drops, but not to zero.  These trends indicate a partial 
mixed-type mode of inhibition, and that the inhibitors bind to a site different from that of the 
substrate. This behavior might explain why the arylstibonate inhibitors have different potency 
towards the three Cdc25 isoforms, because alignment of the amino sequences of all three 
isoforms within the catalytic CX5R motif are identical (Fig. 3c).  Contrary to our initial 
expectations, these findings indicate that the arylstibonic acid moiety is not a mimic of the 
aryl phosphate substrate.  Secondary plots of the enzymological data (not shown) reveal that 
13778 has Ki values of 72 nM and 369 nM for Cdc25a and 25B, while P6949 has Ki values of 
1.7 µM for Cdc25a and 4.7 µM for Cdc25b. 
In conclusion, a focused 40 member arylstibonic acid library was tested against the 
synaptojanin I-5-P and various members of the PTP family. Compounds 13778 and P6949 
were identified as inhibitors of Cdc25a and Cdc25b phosphatases, with 13778 showing 
nanomolar potency, and favorable selectivity. Within the Cdc25 family, 13778 and P6949 
show 100-fold isoform selectivity for Cdc25a and Cdc25b as compared to Cdc25c, which 
makes both compounds a valuable enrichment to the currently existing portfolio of lead 
structures in the search for isoform-selective Cdc25 inhibitors (11). A fascinating aspect of 
these inhibitors is their partial mixed type mode of inhibition, which suggests an allosteric 
effect on the active site structure.  Future improvements would be to identify and characterize 
this site and use this information to design inhibitors with greater potency and/or selectivity.  
As over-expression of Cdc25a and/or Cdc25b, but not Cdc25c, has been detected in 
numerous cancers, these compounds comprise potentially valuable leads for selective 
inhibition of Cdc25a and Cdc25b without affecting the activity of Cdc25c, a feature that 
could be exploited in future drug development (5). 
 
Material and Methods 
 
 
Compounds 
All arylstibonic acids were obtained from the Drug Synthesis and Chemistry Branch, Developmental 
Therapeutics Program, National Cancer Institute, Bethesda, MD.  Compounds were originally 
screened from DMSO solutions and activities of P6949 and 13778 containing the antimony element 
were confirmed from dry powders. Because antimony is paramagnet, the fine features of the 400 MHz 
proton NMR spectra were broadened extensively, and carbon spectra were not obtainable due to due 
unfavorable relaxation effects. The purity of each compound was determined as greater than 97% 
based on proton NMR spectra. Microanalysis was performed by A P Dickerson, University of 
Cambridge. 
P6949 3-(3-stibonophenyl)propanoic acid, 1H NMR (D2O):  2.0-3.0 (m, 4H), 7.0-8.0 (m, 4H); ESI-MS: 
m/z 320.9, 322.9 [MH+].  
 
13778 (E)-3-(3-stibonophenyl)acrylic acid, 1H NMR (DMSO-d6):  6.0-6.5 (m, 1H), 7.0-8.2 (m, 5H), 
12.0-12.8 (br, 1H).  ESI-MS: no signal obtained. 
Microanalysis calculated for C9H9O5Sb: C, 33.89; H, 2.84; N, 0.00.  Found: C, 33.90; H, 2.70; N, 0.00. 
 
Protein Expression and purification 
Human PTEN and rat synaptojanin (amino acids 1-1042), the latter containing the SAC1 and 
5-phosphatase activities were expressed as Glutathione S-transferase (GST)-fusion proteins 
and subsequently purified as described before (12). Protein expression was induced in the E. 
coli strain XL-1 blue for 24 h using 1 mM isopropyl β-D-1-thiogalactopyranoside at 18°C for 
synaptojanin and at 23°C for PTEN. Cells were harvested and stored at -20°C.  The harvested 
cells were re-suspended in lysis buffer containing 50 mM Tris (pH 7.4), 10 mM benzamidine 
hydrochloride, 100 µg/mL soybean trypsin inhibitor, 1 mM 4-(2-aminoethyl)benzenesulfonyl 
fluoride hydrochloride, 2 mM dithiothreitol (DTT) and 1% Triton X-100. Lysis was 
performed by adding lysozyme to the cell suspension at a concentration of 2 mg/mL and 
sonication.  Cell debris was removed by centrifugation at 18000 g for 1 h at 4°C. The 
supernatant was loaded onto a glutathione sepharose column, pre-equilibrated with 50 mM 
Tris (pH 7.4), 140 mM NaCl and 2.7 mM KCl. After loading, the column was washed twice 
with 50 mM Tris (pH 7.4), 140 mM NaCl, 2.7 mM KCl and 2 mM DTT. Another two washes 
were performed using the same buffer with 500 mM NaCl. The GST-tagged PTEN was 
eluted using 20 mM glutathione in 50 mM Tris (pH 7.4), 250 mM NaCl, 20% glycerol and 2 
mM DTT. Protein concentration was determined using Bradford assay. Protein integrity was 
confirmed by Western blot using GST antibody (Novagen). The catalytic domains of Cdc25a, 
b and c with N-terminal His tags were expressed from pET21a in E.coli strain BL21 (DE3) 
and purified by ion exchange (Sepharose SP Fast Flow) and gel filtration (Sephadex G-50) 
chromatography.  Recombinant human His-VHR was obtained from Enzo Life Sciences 
(Exeter, UK) and PTP-β was purchased from Sigma-Aldrich (Dorset, UK). 
 
Phosphatases Assays 
All enzyme preparations were tested for linearity to ensure that suitable amounts of enzyme were 
employed in all kinetic studies. 
Colorimetric quantification of phosphate release using malachite green assay 
Phosphatase activities were determined by measuring the amount of released phosphates for the 5-
inositol phosphatase (IP3 as a substrate) and SAC1 phosphatases activities of synpatojanin1 (12). In 
the case of lipid substrates the phosphatase reaction was started by adding the corresponding 
substrates presented in octylglucoside mixed micelles as described before (13). Reactions were carried 
out in a 96-well plate with buffer containing 4 mM MgCl2, 100 mM Tris (pH 7.4) in a total volume of 
80 µL at 37°C.  Appropriate amounts of denatured enzyme (active enzyme was heated at 95°C for 10 
minutes) were employed in place of active enzyme for comparison (control). In order to stop the 
reaction, same volume of color reagent (5 mM malachite green, 17 mM ammonium heptamolybdate, 
77 mM bismuth citrate and 1.7 M HCl) was added to the assay. The mixture was allowed to develop 
for 10 min and the absorbance was read at 625 nm. 
Colorimetric PTP-β assay using para-nitrophenol phosphate as substrate (p-NPP)  
Phosphatase activity of PTP-β was measured using p-NPP as substrate (14). As above, reactions were 
carried out in a 96-well plate in the presence of 25 mM Hepes (pH 7.4), 50 mM NaCl and 5 mM DTT. 
The reaction was initialized by added p-NPP dissolved in H2O. The enzymatic release of p-
nitrophenol was measured at 405 nm.  
 
3-O-Methylfluorescein Phosphate (OMFP) assay 
Enzyme kinetic studies using OMFP were performed as previously described (10). OMFP was 
dissolved in DMSO to a concentration of 20 mM and then further diluted with 1% DMSO to the 
tested concentrations.  Assays were performed in 100 mM Tris (pH 7.4) containing 2 mM DTT at 
room temperature (20 °C).  
For inhibition studies, enzymes were pre-incubated with arylstibonates at RT for 10 min. Reactions 
were then initialized by adding OMFP. The hydrolysis of OMFP to OMF was monitored by 
measuring the change of fluorescence units (FU) in a 96-well microtiter plate (excitation at 485 nm 
and emission at 525 nm) using a Varian fluorescence spectrophotometer. 
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